Oragenics (NYSEAMERICAN:OGEN) Stock Passes Above 200-Day Moving Average of $0.00
Oragenics (NYSEAMERICAN:OGEN) Stock Passes Above 200-Day Moving Average of $0.00
Shares of Oragenics, Inc. (NYSEAMERICAN:OGEN – Get Rating) crossed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $0.00 and traded as high as $3.58. Oragenics shares last traded at $3.37, with a volume of 7,412 shares.
在周二的交易中，Oragenics, Inc.（纽约证券交易所美国证券交易所代码：OGEN — Get Rating）的股价突破了其两百天移动平均线。该股的两百天移动平均线为0.00美元，交易价格高达3.58美元。Oragenics股票最后一次交易价格为3.37美元，成交量为7,412股。
Oragenics Price Performance
Oragenics 价格表现
The firm has a market capitalization of $6.60 million, a P/E ratio of -25.92 and a beta of 0.19.
该公司的市值为660万美元，市盈率为-25.92，beta值为0.19。
Institutional Inflows and Outflows
机构流入和流出
Hedge funds have recently bought and sold shares of the business. Renaissance Technologies LLC grew its holdings in shares of Oragenics by 116.5% during the 2nd quarter. Renaissance Technologies LLC now owns 209,600 shares of the biotechnology company's stock worth $73,000 after acquiring an additional 112,800 shares during the period. Millennium Management LLC grew its holdings in shares of Oragenics by 591.6% during the 2nd quarter. Millennium Management LLC now owns 128,733 shares of the biotechnology company's stock worth $45,000 after acquiring an additional 110,119 shares during the period. Finally, State Street Corp grew its holdings in shares of Oragenics by 8.1% during the 1st quarter. State Street Corp now owns 495,563 shares of the biotechnology company's stock worth $171,000 after acquiring an additional 37,338 shares during the period. Hedge funds and other institutional investors own 9.31% of the company's stock.
对冲基金最近买入和卖出了该公司的股票。Renaissance Technologies LLC在第二季度将其持有的Oragenics的股票增加了116.5％。Renaissance Technologies LLC在此期间又收购了11,800股股票后，现在拥有这家生物技术公司的209,600股股票，价值73,000美元。千禧管理有限责任公司在第二季度将其持有的Oragenics的股票增加了591.6％。Millennium Management LLC在此期间又收购了110,119股股票后，现在拥有这家生物技术公司的128,733股股票，价值45,000美元。最后，State Street Corp在第一季度将其持有的Oragenics的股票增加了8.1％。State Street Corp在此期间又收购了37,338股股票后，现在拥有这家生物技术公司的495,563股股票，价值17.1万美元。对冲基金和其他机构投资者拥有该公司9.31％的股票。
Oragenics Company Profile
Oragenics 公司简介
(Get Rating)
（获取评分）
Oragenics, Inc develops antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus; and Terra CoV-2, an intramuscular vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.
Oragenics, Inc在美国开发用于传染病的抗生素。该公司参与NT-CoV-2-1（一种提供新型严重急性呼吸综合征冠状病毒免疫力的鼻内候选疫苗）的开发和商业化；以及提供对新型严重急性呼吸综合征冠状病毒免疫的肌肉注射候选疫苗Terra CoV-2。
Read More
阅读更多
- Get a free copy of the StockNews.com research report on Oragenics (OGEN)
- Weight Watchers Reshapes Itself with a Game-Changer Acquisition
- Two Tiny Mining Stocks Worth Considering for the Next Gold Rush
- Nano Dimension Prints Growth: Enters Hypergrowth Phase
- CF Is Set To Harvest The Bull Run In Agricultural Stocks
- Oracle Dips But The Trend Is Strong
- 免费获取 StockNews.com 关于 Oragenics (OGEN) 的研究报告
- Weight Watchers 通过收购改变游戏规则的方式重塑自我
- 下一次淘金热值得考虑的两只小型矿业股
- Nano Dimension 打印成长：进入超生长阶段
- CF 将收获农业股的牛市
- 甲骨文下跌但趋势强劲
Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.
接收 Oragenics Daily 的新闻和评级 -在下面输入您的电子邮件地址，即可通过Marketbeat.com的免费每日电子邮件时事通讯接收Oragenics及相关公司的最新新闻和分析师评级的简明每日摘要。
译文内容由第三方软件翻译。